Wednesday, August 20, 2025 8/20/2025

A1 ADENOSINE AGONIST: ANTINOCICEPTIVE EFFECTS

Award Number: R43NS050918
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/30/2004
PERIOD OF PERFORMANCE END DATE: 03/29/2005

Group Awards By:

View Award Description

A1 ADENOSINE AGONIST: ANTINOCICEPTIVE EFFECTS - DESCRIPTION (provided by applicant): The current Phase I SBIR Grant application by Inotek Pharmaceuticals Corporation proposes to test the antinociceptive effect of a novel A1 receptor agonist in rat models. As preliminary data we present evidence in cultured cells expressing various human Al receptor subtypes that the compound PJ8-75 is ultrapotent and ultraselective for the A1 adenosine receptor. Prior data indicate that adenosine, via the A1 receptor subtype, exerts antinociceptive effects. The current proposal will determine whether the applicants' A1 agonist compounds exert antinociceptive effects in vivo. The ligand will be administered intrathecally. The effect of the A1 agonist will be tested on thermo- and mechano-nociception in the carrageenan-induced acute hyperalgesia test and in the chronic traumatic neuropathy model (Seltzer) in rats. Minimally effective dose of the compound will be determined. In addition, combination approaches will be tested for antinociception. In the final aim we will conduct preliminary in-house toxicology studies with the compound. Efficacy of the ligand in the in vivo models, coupled with a benign toxicology profile, will trigger the Phase II SBIR Stage of the proposal, whereby formal toxicology and human safety and early efficacy evaluation will be conducted.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2004 ( Subtotal = $193,885 )
2004	2004	INOTEK PHARMACEUTICALS CORPORATION	100 CUMMINGS CENTERSUITE 419E	BEVERLY	MA	01915	ESSEX	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	9/27/2004	NEW	$193,885
														Subtotal = $193,885

Grand Total All Awards = $193,885

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A1 ADENOSINE AGONIST: ANTINOCICEPTIVE EFFECTS

Award Number: R43NS050918

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/30/2004

PERIOD OF PERFORMANCE END DATE: 03/29/2005

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer